Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL51254 | 0.85 | SLC6A2 (0.50) | SLC6A2SLC6A4SLC6A3GRM2TAAR1 | |
| SCHEMBL873444 | 0.85 | SLC6A2 (0.50) | SLC6A2SLC6A4SLC6A3GRM2TAAR1 | |
| SCHEMBL2186411 | 0.85 | SLC6A2 (0.50) | SLC6A2SLC6A4SLC6A3GRM2TAAR1 | |
| Methane SCHEMBL28820455 | 0.83 | SLC6A2 (0.48) | SLC6A2SLC6A4SLC6A3GRM2TAAR1 | |
| SCHEMBL8485 | 0.82 | SLC6A2 (0.42) | SLC6A2SLC6A4SLC6A3GRM2TAAR1 | |
| SCHEMBL30581420 | 0.81 | MAPT (0.36) | SLC6A2SLC6A4SLC6A3TAAR1 | |
| Hydrochloric Acid SCHEMBL12503316 | 0.81 | KDM4E (0.41) | SLC6A2SLC6A4SLC6A3GRM2TAAR1 | |
| Dimethylamine SCHEMBL28875130 | 0.78 | SLC6A2 (0.44) | SLC6A2SLC6A4SLC6A3GRM2TAAR1 | |
| SCHEMBL9597591 | 0.77 | LMNA (0.50) | SLC6A2TAAR1MEN1KMT2A | |
| SCHEMBL9597593 | 0.77 | LMNA (0.50) | SLC6A2TAAR1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 205 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009018844-A1 | THIAZOLE-PIPERIDINE DERIVATIVES FOR TREATMENT OF HYPERPROLIFERATIVE DISEASES | ORIDIS BIOMED FORSCHUNGS- UND ENTWICKLUNGS GMBH (AT) | 2009-02-12 | — | — | WO | claimed |
| EP-1832585-A1 | Thiazole-piperidine derivatives for treatment of hyperproliferative diseases | ORIDIS BIOMED Forschungs- und Entwicklungs GmbH (AT) | 2007-09-12 | — | — | EP | claimed |
| US-12012399-B2 | Microbiocidal quinoline dihydro-(thiazine)oxazine derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2024-06-18 | — | — | US | disclosed |
| EP-3929197-B1 | INTERMEDIATES FOR THE SYNTHESIS OF MICROBIOCIDAL HETEROBICYCLIC DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2024-03-06 | — | — | EP | disclosed |
| US-11744246-B2 | Preparation of mammalian oocyte for fertilization via a soluble human PH20 hyaluronidase polypeptide | SYNGENTA PARTICIPATIONS AG (CH) | 2023-09-05 | — | — | US | disclosed |
| EP-3334736-B1 | MICROBIOCIDAL HETEROBICYCLIC DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2023-06-28 | — | — | EP | disclosed |
| US-11584740-B2 | Microbiocidal quinoline (thio)carboxamide derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2023-02-21 | — | — | US | disclosed |
| EP-3853207-B1 | MICROBIOCIDAL QUINOLINE CARBOXAMIDE DERIVATIVES | SYNGENTA CROP PROTECTION AG (CH) | 2022-10-19 | — | — | EP | disclosed |
| US-11241011-B2 | Microbiocidal quinoline (thio)carboxamide derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2022-02-08 | — | — | US | disclosed |
| US-20220015364-A1 | MICROBIOCIDAL QUINOLINE (THIO)CARBOXAMIDE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2022-01-20 | — | — | US | disclosed |
| EP-3601228-B1 | MICROBIOCIDAL QUINOLINE (THIO)CARBOXAMIDE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2022-01-19 | — | — | EP | disclosed |
| WO-2011011139-A2 | METHOD AND MATERIALS FOR REVERSE PATTERNING | DOW CORNING CORPORATION (US) | 2011-01-27 | — | — | WO | disclosed |
| WO-2010071227-A1 | ALUMINIUM COMPLEXES AND USE THEREOF AS A CATALYST IN INTRAMOLECULAR RING CLOSURE REACTIONS | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2010-06-24 | — | — | WO | disclosed |
| WO-2009018844-A1 | THIAZOLE-PIPERIDINE DERIVATIVES FOR TREATMENT OF HYPERPROLIFERATIVE DISEASES | ORIDIS BIOMED FORSCHUNGS- UND ENTWICKLUNGS GMBH (AT) | 2009-02-12 | — | — | WO | disclosed |
| EP-1832585-A1 | Thiazole-piperidine derivatives for treatment of hyperproliferative diseases | ORIDIS BIOMED Forschungs- und Entwicklungs GmbH (AT) | 2007-09-12 | — | — | EP | disclosed |
| US-5696263-A | Antiviral acyclic phosphonomethoxyalkylsubstituted alkenyl and alkynyl purine and pyrimidine derivatives | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) | 1997-12-09 | — | — | US | disclosed |
| EP-0630381-B1 | ANTIVIRAL ACYCLIC PHOSPHONOMETHOXYALKYL SUBSTITUTED, ALKENYL AND ALKYNYL PURINE AND PYRIMIDINE DERIVATIVES | ACAD OF SCIENCE CZECH REPUBLIC (CZ) | 1997-04-09 | — | — | EP | disclosed |
| EP-0630381-A4 | ANTIVIRAL ACYCLIC PHOSPHONOMETHOXYALKYL SUBSTITUTED, ALKENYL AND ALKYNYL PURINE AND PYRIMIDINE DERIVATIVES. | — | 1995-01-04 | — | — | EP | disclosed |
| EP-0630381-A1 | ANTIVIRAL ACYCLIC PHOSPHONOMETHOXYALKYL SUBSTITUTED, ALKENYL AND ALKYNYL PURINE AND PYRIMIDINE DERIVATIVES. | ACAD OF SCIENCE CZECH REPUBLIC (CS) | 1994-12-28 | — | — | EP | disclosed |
| WO-1993007157-A1 | ANTIVIRAL ACYCLIC PHOSPHONOMETHOXYALKYL SUBSTITUTED, ALKENYL AND ALKYNYL PURINE AND PYRIMIDINE DERIVATIVES | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OFTHE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) | 1993-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220015364-A1 | MICROBIOCIDAL QUINOLINE (THIO)CARBOXAMIDE DERIVATIVES | IFNG, TLR1, IDO1 | SLC6A2 4195/4885SLC6A4 3938/4885SLC6A3 4357/4885 |
| US-11241011-B2 | Microbiocidal quinoline (thio)carboxamide derivatives | IFNG, TLR1, IDO1 | SLC6A2 4195/4885SLC6A4 3938/4885SLC6A3 4357/4885 |
| US-12012399-B2 | Microbiocidal quinoline dihydro-(thiazine)oxazine derivatives | TLR1, TLR5, IDO1 | SLC6A2 4407/4885SLC6A4 3955/4885SLC6A3 4312/4885 |
| US-11744246-B2 | Preparation of mammalian oocyte for fertilization via a soluble human PH20 hyaluronidase polypeptide | PHF20, FUCA1, ZP1 | SLC6A2 4785/4885SLC6A4 4580/4885SLC6A3 4778/4885 |
| US-11584740-B2 | Microbiocidal quinoline (thio)carboxamide derivatives | IFNG, TLR1, IDO1 | SLC6A2 4195/4885SLC6A4 3938/4885SLC6A3 4357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.